FRAME STUDY: THE FOUNDATION EFFECT OF REBUILDING BONE WITH ONE YEAR OF ROMOSOZUMAB LEADS TO CONTINUED LOWER FRACTURE RISK AFTER TRANSITION TO DENOSUMAB

被引：0
|
作者：
Cosman, F. [1 ]
Crittenden, D. B. [2 ]
Ferrari, S. [3 ]
Khan, A. [4 ]
Lanes, N. E. [5 ]
Lippuner, K. [6 ,7 ]
Matsumoto, T. [8 ]
Milisiont, C. E. [2 ]
Libanati, C. [9 ]
Grauers, A. [2 ]
机构：
[1] Columbia Univ, Helen Hayes Hosp, W Haverstraw, NY USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Geneva Univ Hosp, Geneva, Switzerland
[4] McMaster Univ, Hamilton, ON, Canada
[5] UC Davis Med Ctr, Sacramento, CA USA
[6] Bern Univ Hosp, Inselspital, Osteoporosis Policlin, Bern, Switzerland
[7] Univ Bern, Bern, Switzerland
[8] Univ Tokushima, Tokushima, Japan
[9] UCB Pharma, Brussels, Belgium
来源：
OSTEOPOROSIS INTERNATIONAL | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P443
引用
收藏
页码：S268 / S268
页数：1
相关论文
共 41 条
  • [1] FRAME STUDY: THE FOUNDATION EFFECT OF REBUILDING BONE WITH ONE YEAR OF ROMOSOZUMAB LEADS TO CONTINUED LOWER FRACTURE RISK AFTER TRANSITION TO DENOSUMAB
    Cosman, F.
    Crittenden, D. B.
    Ferrari, S.
    Khan, A.
    Lane, N. E.
    Lippuner, K.
    Matsumoto, T.
    Milmont, C. E.
    Libanati, C.
    Grauer, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 217 - 218
  • [2] FRAME Study: The Foundation Effect of Rebuilding Bone With One Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
    Cosman, Felicia
    Crittenden, Daria B.
    Ferrari, Serge
    Khan, Aliya
    Lane, Nancy
    Lippuner, Kurt
    Matsumoto, Toshio
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S37 - S38
  • [3] FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
    Cosman, Felicia
    Crittenden, Daria B.
    Ferrari, Serge
    Khan, Aliya
    Lane, Nancy E.
    Lippuner, Kurt
    Matsumoto, Toshio
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (07) : 1219 - 1226
  • [4] The Placebo-Controlled Fracture Study in Postmenopausal Women with Osteoporosis: The Foundation Effect of Rebuilding Bone with One Year of Romosozumab Leads to Continued Lower Fracture Risk after Transition to Denosumab
    Cosman, Felicia
    Crittenden, Daria B.
    Ferrari, Serge
    Khan, Aliya
    Lane, Nancy E.
    Lippuner, Kurt
    Matsumoto, Toshio
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [5] One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
    Lewiecki, E. Michael
    Dinavahi, Rajani V.
    Lazaretti-Castro, Marise
    Ebeling, Peter R.
    Adachi, Jonathan D.
    Miyauchi, Akimitsu
    Gielen, Evelien
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (03) : 419 - 428
  • [6] One Year of Romosozumab Followed by One Year of Denosumab Compared With Two Years of Denosumab: BMD and Fracture Results From the FRAME and FRAME Extension Studies
    Betah, Donald
    Ferrari, Serge
    Timoshanko, Jen
    Wang, Zhenxun
    McClung, Michael
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 18 - 18
  • [7] ONE YEAR OF ROMOSOZUMAB FOLLOWED BY ONE YEAR OF DENOSUMAB VERSUS TWO YEARS OF DENOSUMAB: BMD AND FRACTURE RESULTS FROM THE FRAME AND FRAME EXTENSION STUDIES
    Cosman, F.
    Oates, M.
    Betah, D.
    Ferrari, S.
    Timoshanko, J.
    Wang, Z.
    McClung, M.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S53 - S53
  • [8] Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension.
    Lewiecki, E. Michael
    Dinavahi, Rajani V.
    Lazaretti-Castro, Marise
    Ebeling, Peter R.
    Adachi, Jonathan D.
    Miyauchi, Akimitsu
    Gielen, Evelien
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S24 - S24
  • [9] One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reduction: Analysis for the Japanese Population of Phase 3 FRAME Extension
    Miyauchi, Akimitsu
    Dinavahi, Rajani
    Crittenden, Daria Barry
    Yang, Wenjing
    Maddox, Judy
    Grauer, Andreas
    Hamaya, Etsuro
    Nakamura, Yoichi
    Shimauchi, Junichiro
    Libanati, Cesar
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 261 - 261
  • [10] Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up
    Anne M. Horne
    Borislav Mihov
    Ian R. Reid
    Calcified Tissue International, 2019, 105 : 107 - 108
12345